Abstract

The gut-brain axis (GBA) is a bidirectional communication network between the gastrointestinal tract and the central nervous system, influencing neurological health and disease. Emerging research highlights the role of gut microbiota and their metabolites in regulating brain function, leading to new pharmacological approaches in treating neurological disorders. This article explores the potential of the GBA as a target for novel drug therapies, including psychobiotics, microbiota-derived metabolites, and neuroprotective agents, offering promising new horizons in the treatment of neurodegenerative diseases, mood disorders, and cognitive impairments